A practical reference on reconstitution: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-09. Anything still debated is marked as such rather than presented as settled.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Peptide, oligopeptide, polypeptide | Usage varies; polypeptide often implies a longer chain |
| Purity assessment | High-performance liquid chromatography | Often reversed-phase; reported as area percent with method and wavelength stated |
| Identity confirmation | Mass spectrometry | Observed mass compared with theoretical mass within instrument tolerance |
| Water content (lyophilized) | Karl Fischer titration | Residual moisture can affect stability and weighing accuracy |
| Container compatibility | Low-binding polypropylene | Glass may adsorb some peptides; plastic additives can leach |
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
Thorium (90Th) has seven naturally occurring isotopes but none are stable. One isotope, 232Th, is relatively stable, with a half-life of 1.40×1010 years, considerably longer than the age of the Earth, and even slightly longer than the generally accepted age of the universe. This isotope makes up nearly all natural thorium, so thorium was considered to be mononuclidic. However, in 2013, IUPAC reclassified thorium as binuclidic, due to large amounts of 230Th in deep seawater. Thorium has a characteristic terrestrial isotopic composition and thus a standard atomic weight can be given. Thirty-one radioisotopes have been characterized, with the most stable being 232Th, 230Th with a half-life of 75,400 years, 229Th with a half-life of 7,916 years, and 228Th with a half-life of 1.91 years. All of the remaining radioactive isotopes have half-lives that are less than thirty days and the majority of these have half-lives that are less than ten minutes. One isotope, 229Th, has a nuclear isomer (or metastable state) with a remarkably low excitation energy, recently measured to be 8.355733554021(8) eV It has been proposed to perform laser spectroscopy of the 229Th nucleus and use the low-energy transition for the development of a nuclear clock of extremely high accuracy. The known isotopes of thorium range in mass number from 207 to 238.
=== Weight and blood pressure === Empagliflozin causes moderate reductions in blood pressure and body weight. These effects are likely due to the excretion of glucose in the urine and a slight increase in urinary sodium excretion. In clinical trials, participants with type 2 diabetes taking empagliflozin with other diabetic medications lost an average of 2% of their baseline body weight. Empagliflozin use has been associated with clinically meaningful weight loss, with a higher proportion of individuals achieving weight loss greater than 5% of their baseline weight compared to placebo. The degree of weight loss may vary depending on the dosage (10mg or 25mg). While weight loss can contribute to improved glycaemic control, the primary glucose-lowering effect of empagliflozin occurs independently through increased urinary glucose excretion. The same extent of weight loss was also observed in a study with heart failure patients taking empagliflozin. Empagliflozin has been shown to reduce systolic blood pressure by 3 to 5 millimeters of mercury (mmHg) without changes in pulse rate. A greater percentage of people with uncontrolled blood pressure at baseline, achieved controlled blood pressure (i.e. systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg) after taking empagliflozin at 24 weeks. The effects on blood pressure and body weight are generally viewed as favorable, as many people with type 2 diabetes have high blood pressure or are overweight or obese.
Recent research has expanded understanding of snake venom LAAOs (sv-LAAOs), revealing their role in venom-induced tissue damage through oxidative stress and induction of cell death pathways such as autophagy, apoptosis, and necrosis. Structural studies have clarified their three-domain organization and active site variability, which underlie substrate specificity and functional diversity. In addition to their antimicrobial properties, sv-LAAOs exhibit selective cytotoxicity against tumor cells, making them a subject of growing interest for therapeutic development.
Sources: en.wikipedia.org
If we cannot destroy the drug menace in America, then it will surely in time destroy us." His strategy involved both treatment and interdiction: "I am proposing the appropriation of additional funds to meet the cost of rehabilitating drug users, and I will ask for additional funds to increase our enforcement efforts to further tighten the noose around the necks of drug peddlers, and thereby loosen the noose around the necks of drug users." He singled out heroin and broadened the scope beyond the US: "To wage an effective war against heroin addiction, we must have international cooperation. In order to secure such cooperation, I am initiating a worldwide escalation in our existing programs for the control of narcotics traffic." Later the same day, Nixon held a news conference at the White House, where he described drug abuse as "America's public enemy number one." He announced, "In order to fight and defeat this enemy, it is necessary to wage a new, all-out offensive. ... This will be a worldwide offensive dealing with the problems of sources of supply ... It will be government wide, pulling together the nine different fragmented areas within the government in which this problem is now being handled, and it will be nationwide in terms of a new educational program." Nixon also stated that the problem wouldn't end with the addiction of soldiers in the Vietnam War. He pledged to ask Congress for a minimum of $350 million for the anti-drug effort (when he took office in 1969, the federal drug budget was $81 million).
== Biomarker == Fragments derived from the ANP precursor, including the signal peptide, NT-ProANP (N-terminal pro-ANP) and ANP, have been detected in human blood. ANP (28 residues long) is the active hormone while NT-proANP (98 residues) is the remaining part of proANP after cleavage by corin. ANP and associated peptides are used as biomarkers for cardiovascular diseases such as stroke, coronary artery disease, myocardial infarction and heart failure. A part of NT-proANP called mid-regional pro-atrial natriuretic peptide (MR-proANP) is a highly sensitive biomarker in heart failure. MR-proANP levels below 120 pmol/L can be used to effectively rule out acute heart failure. MR-proANP is measured using antibodies that bind to two consecutive parts of NT-proANP, residue number 53–72 and 73–90. In contrast, traditional NT-proANP measurement use antibodies that bind to the N-terminal of NT-proANP. In either case, antibodies are only able to determine the amount of peptides matching their epitope fragments. They largely cannot differentiate between a cleaved part (NT-proANP, ANP) and the uncleaved precursor (proANP). Large amounts of ANP secretion has been noted to cause electrolyte disturbances (hyponatremia) and polyuria. These indications can be a marker of a large atrial myxoma.
=== Veterinary use === Chosen for its high therapeutic index, carfentanil was first sold in 1986 under the brand name "Wildnil" for use in combination with an α2-receptor agonist as a tranquilizing agent for large ungulates, elephants, and large carnivores. Commercial production of Wildnil ceased in 2003; the drug is now available only in compounded form and not available for veterinary use due to human abuse. Since then, etorphine has become the standard tranquilizing agent for large mammals, with diprenorphine as the preferred reversal agent. Diprenorphine was also used previously to reverse the effects of carfentanil.
By increasing the temperature and pressure he forced the liquid into a supercritical fluid state where by dropping the pressure he could instantly gasify and remove the liquid inside the aerogel, avoiding damage to the delicate three-dimensional network. While this can be done with ethanol, the high temperatures and pressures lead to dangerous processing conditions. A safer, lower temperature and pressure method involves a solvent exchange. This is typically done by exchanging the initial aqueous pore liquid for a CO2-miscible liquid such as ethanol or acetone, then onto liquid carbon dioxide, and then bringing the carbon dioxide above its critical point. A variant on this process involves the direct injection of supercritical carbon dioxide into the pressure vessel containing the aerogel. The result of either process exchanges the initial liquid from the gel with carbon dioxide, without allowing the gel structure to collapse or lose volume.
Sources: en.wikipedia.org
Allow the sealed vial to equilibrate to room temperature so condensation does not form on the powder or solution. Wipe the exterior with a suitable disinfectant if the workspace requires it. Open the vial in a clean, draft-free area to reduce contamination.
Vortexing creates rapid air-liquid interfaces that can cause foaming and promote aggregation. Gentle inversion or slow swirling usually dissolves the peptide with less physical stress. Some sequences tolerate vortexing, but minimizing shear is a general precaution.
A certificate of analysis usually reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes water content or counterion. It may also list lot number, storage recommendations, and handling notes. Exact content varies by supplier and product type.
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.